Kathryn C Fitzgerald1, Anne Damian2, Devon Conway3, Ellen M Mowry1. 1. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA/Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 2. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3. Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
Abstract
OBJECTIVE: The objective of this study is to assess the association between vascular comorbidity burden with clinical and imaging features of disease burden in a large population of people with multiple sclerosis (MS). METHODS: We included participants from the MS Partners Advancing Technology Health Solutions (MS PATHS) cohort. We evaluated if vascular comorbidities (diabetes, hypertension, and dyslipidemia) or a composite sum of comorbidities was associated with MS characteristics, including objective neurologic function assessments and quantitative brain magnetic resonance imaging (MRI) measurements in propensity score-weighted models. RESULTS: In total, 11,506 participants (6409 (55%) with brain MRI) were included. Individuals with 2+ vascular comorbidities had slower walking speed (standard deviation (SD) = -0.49; 95% confidence interval (CI) = -0.78, -0.19; p = 0.001), slower manual dexterity (SD = -0.41; 95% CI = -0.57, -0.26; p < 0.0001), and fewer correct scores on cognitive processing speed (SD = -0.11; 95% CI = -0.20, -0.02; p = 0.02) versus those with no comorbidities. Those with 2+ had lower brain parenchymal (-0.41%, 95% CI = -0.64, -0.17) and gray matter fractions (-0.30%, 95% CI = -0.49, -0.10), including reduced cortical (-10.10 mL, 95% CI = -15.42, -4.78) and deep (-0.44 mL, 95% CI = -0.84, -0.04) gray matter volumes versus those with no comorbidity. CONCLUSION: Increased vascular comorbidity burden was associated with clinical and imaging markers of neurologic dysfunction and neurodegeneration in MS. Strategies to optimize comorbidity management in people with MS are warranted.
OBJECTIVE: The objective of this study is to assess the association between vascular comorbidity burden with clinical and imaging features of disease burden in a large population of people with multiple sclerosis (MS). METHODS: We included participants from the MS Partners Advancing Technology Health Solutions (MS PATHS) cohort. We evaluated if vascular comorbidities (diabetes, hypertension, and dyslipidemia) or a composite sum of comorbidities was associated with MS characteristics, including objective neurologic function assessments and quantitative brain magnetic resonance imaging (MRI) measurements in propensity score-weighted models. RESULTS: In total, 11,506 participants (6409 (55%) with brain MRI) were included. Individuals with 2+ vascular comorbidities had slower walking speed (standard deviation (SD) = -0.49; 95% confidence interval (CI) = -0.78, -0.19; p = 0.001), slower manual dexterity (SD = -0.41; 95% CI = -0.57, -0.26; p < 0.0001), and fewer correct scores on cognitive processing speed (SD = -0.11; 95% CI = -0.20, -0.02; p = 0.02) versus those with no comorbidities. Those with 2+ had lower brain parenchymal (-0.41%, 95% CI = -0.64, -0.17) and gray matter fractions (-0.30%, 95% CI = -0.49, -0.10), including reduced cortical (-10.10 mL, 95% CI = -15.42, -4.78) and deep (-0.44 mL, 95% CI = -0.84, -0.04) gray matter volumes versus those with no comorbidity. CONCLUSION: Increased vascular comorbidity burden was associated with clinical and imaging markers of neurologic dysfunction and neurodegeneration in MS. Strategies to optimize comorbidity management in people with MS are warranted.
Authors: Eleni S Vasileiou; Angeliki G Filippatou; Daniela Pimentel Maldonado; Grigorios Kalaitzidis; Henrik Ehrhardt; Jeffrey Lambe; Shiv Saidha; Elias S Sotirchos; Ellen M Mowry; Peter A Calabresi; Kathryn C Fitzgerald Journal: Brain Date: 2021-12-31 Impact factor: 13.501
Authors: Devon S Conway; Farren Bs Briggs; Ellen M Mowry; Kathryn C Fitzgerald; Carrie M Hersh Journal: Mult Scler Relat Disord Date: 2022-06-15 Impact factor: 4.808
Authors: Federica Felicetti; Silvia Tommasin; Maria Petracca; Laura De Giglio; Flavia Gurreri; Antonio Ianniello; Riccardo Nistri; Carlo Pozzilli; Serena Ruggieri Journal: Front Nutr Date: 2022-06-16
Authors: Ruth Ann Marrie; Ronak Patel; Chase R Figley; Jennifer Kornelsen; James M Bolton; Lesley A Graff; Erin L Mazerolle; Carl Helmick; Md Nasir Uddin; Teresa D Figley; James J Marriott; Charles N Bernstein; John D Fisk Journal: Front Neurol Date: 2022-05-24 Impact factor: 4.086
Authors: Antonio Reia; Martina Petruzzo; Fabrizia Falco; Teresa Costabile; Matteo Conenna; Antonio Carotenuto; Maria Petracca; Giuseppe Servillo; Roberta Lanzillo; Vincenzo Brescia Morra; Marcello Moccia Journal: Brain Sci Date: 2021-04-16
Authors: Kathryn C Fitzgerald; Matthew D Smith; Sol Kim; Elias S Sotirchos; Michael D Kornberg; Morgan Douglas; Bardia Nourbakhsh; Jennifer Graves; Ramandeep Rattan; Laila Poisson; Mirela Cerghet; Ellen M Mowry; Emmanuelle Waubant; Shailendra Giri; Peter A Calabresi; Pavan Bhargava Journal: Cell Rep Med Date: 2021-10-19
Authors: Massimiliano Mirabella; Pietro Annovazzi; Wallace Brownlee; Jeffrey A Cohen; Christoph Kleinschnitz; Christian Wolf Journal: Front Neurol Date: 2022-04-15 Impact factor: 4.086